Uterine Cancer Diagnostic Testing Market
Uterine Cancer Diagnostic Testing Market Study by Ultrasound Scanning, Biopsy, and Blood Test for Endometrial Carcinoma and Uterine Sarcoma from 2024 to 2034)
Analysis of Uterine Cancer Diagnostic Testing Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Uterine Cancer Diagnostic Testing Market Outlook (2024 to 2034)
The global uterine cancer diagnostic testing market size is expected to reach a size of US$ 3.23 billion in 2024. The market has been forecasted to climb to a value of US$ 6.76 billion by the end of 2034, expanding at a CAGR of 7.7% over the next ten years.
Uterine cancer diagnostic tests include ultrasound scanning, biopsy procedures, and blood tests. Utilizing sound waves, ultrasound scanning tests produce images of the uterus and ovaries. Abdominal and transvaginal ultrasound scanning are the two types of ultrasound scanning used in uterine cancer diagnostic tests. While transvaginal scanning involves inserting a transducer wand into the vagina to scan or create an image, abdominal scanning involves scanning a full bladder across the abdomen using a tiny device called a transducer.
Key Market Growth Drivers
- The need for diagnostic testing to identify and treat uterine cancer early is increasing as the disease's incidence rises worldwide.
- Precision and effectiveness of diagnosing uterine cancer have increased due to technological developments in genetic testing, biomarker identification, and imaging methods (such as MRI and ultrasound).
- Demand for diagnostic testing among older women is predicted to rise in tandem with the growing global aging population and the rising incidence of uterine cancer.
- Public health campaigns and initiatives promoting awareness of women's health issues, particularly uterine cancer, and encouraging early detection through routine screenings are contributing to the expansion of the uterine cancer diagnostic testing market size.
- Funding for uterine cancer diagnostic testing programs is frequently included in government initiatives aimed at cancer prevention, screening, and treatment.
| Report Attribute | Details |
|---|---|
| Uterine Cancer Diagnostic Testing Market Size (2024E) | US$ 3.23 Billion |
| Projected Market Value (2034F) | US$ 6.76 Billion |
| Global Market Growth Rate (2024 to 2034) | 7.7% CAGR |
| Latin America Market Growth Rate (2024 to 2034) | 4.8% CAGR |
| North America Market Growth Rate (2034) | 5.6% CAGR |
| Specialized Clinics Segment Value (2024) | US$ 653.7 Million |
| Biopsy Segment Value (2024) | US$ 1.81 Billion |
| Key Companies Profiled | Ariad Pharmaceuticals, Inc.; Abbott Laboratories; Becton, Dickinson & Co.; GlaxoSmithKline Plc; Merck & Co., Inc.; Novartis AG; Sanofi; Siemens Healthcare Inc.; Roche Ltd.; MiMARK Diagnostics. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why is There an Uptick in Uterine Cancer Diagnostic Testing?
“Increasing Awareness of Early Diagnosis and Intervention for Uterine Cancer”
Risk factors for uterine cancer development include obesity, hyperplasia, and excessive drug use for breast cancer treatment. One of the main signs of endometrial cancer is abnormal vaginal bleeding, followed by pelvic pain and sudden vaginal discharge. Uterine sarcoma is diagnosed at a later stage and exhibits no symptoms, in contrast to endometrial carcinoma.
Blood tests, biopsy procedures, and ultrasound scanning are all part of the diagnostic testing for uterine cancer. Utilizing sound waves, ultrasound scanning tests produce images of the uterus and ovaries.
What are the Challenges for Uterine Cancer Diagnostic Testing?
“Ambiguous Early-Stage Symptoms and Disparities in Healthcare Infrastructure”
Early-stage uterine cancer symptoms are ambiguous or similar to those of other benign conditions that are causing diagnostic delays. In contrast to certain other cancers (such as cervical cancer detected by Pap smears), there is no common test to identify uterine cancer in women who do not exhibit any symptoms, which causes symptoms to not show up until later.
It is possible for certain diagnostic procedures such as biopsies and imaging studies, to incorrectly identify between benign and malignant uterine conditions, which results in false positives or negatives. Inequalities in the infrastructure and availability of advanced diagnostic tests are also preventing some regions thus delaying diagnosis and treatment.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
Europe is witnessing a rise in the number of uterine cancer cases. North America is expected to hold 46.5% of the global uterine cancer diagnostic testing market share in 2024. China has become a lucrative market for uterine cancer diagnostic testing providers because of a rise in government funding and healthcare spending. The market for uterine cancer diagnostic testing in China is projected to grow at a significant pace as a result of government reimbursement policies for women's health screenings and treatments.
What are Market Players Leveraging to Stay Ahead in the United States?
“Wide Availability of Affordable Diagnosis and Treatment Options”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 1.35 Billion |
| Growth Rate (2024 to 2034) | 5.7% CAGR |
| Projected Value (2034F) | US$ 2.36 Billion |
Uterine cancer diagnostic testing market growth in the United States over the forecast period is projected to be driven by the availability of affordable diagnosis and treatment options. The increasing population of older women in the country is also a major driver for market growth.
- The National Institutes of Health claims that the United States has a high incidence of uterine cancer as a result of rising rates of post-menopausal women and an obese population brought on by unhealthy lifestyle choices.
Why is Demand for Uterine Cancer Diagnostic Testing Rising in Brazil?
“Demographic Shift toward Older Population”
| Attribute | Brazil |
|---|---|
| Market Value (2024E) | US$ 60.39 Million |
| Growth Rate (2024 to 2034) | 5% CAGR |
| Projected Value (2034F) | US$ 98.37 Million |
Uterine cancer is one of the most common cancers among women in Brazil. Brazil has a sizable aging population, and as people age, so does their risk of developing uterine cancer. The increasing incidence and ensuing need for diagnostic testing are both influenced by the demographic shift towards an older population.
Category-wise Insights
The uterine cancer diagnostic testing market is categorized into endometrial carcinoma and uterine sarcoma in terms of cancer type, of which the former is expected to hold a 91.2% market share in 2024. By diagnostic test type, the market is segmented into ultrasound scanning, biopsy, and blood tests, of which biopsy is set to hold a market share of 56.1%.
In terms of end users, the market is divided into hospitals, ambulatory surgical centers, cancer research centers, specialized clinics, and diagnostic laboratories, of which the diagnostic laboratories are set to hold a market share of 41.3% in 2024.
Why is Ultrasound Scanning the Primary Choice for Assessing Uterine Abnormalities?
“Non-Invasive and Radiation-Free Nature of Ultrasound Scanning”
| Attribute | Ultrasound Scanning |
|---|---|
| Segment Value (2024E) | US$ 1.33 Billion |
| Growth Rate (2024 to 2034) | 8.2% CAGR |
| Projected Value (2034F) | US$ 2.49 Billion |
The first imaging modality of choice for assessing uterine abnormalities is ultrasound scanning because it is non-invasive and radiation-free, thus reducing the discomfort for the patient and enabling more examinations when needed. Even in environments with limited resources, ultrasound equipment is widely accessible in healthcare settings, including clinics and hospitals. This is a key uterine cancer diagnostic testing market trend.
More people are opting for this because of its comparatively lower cost when compared to other imaging modalities. Ultrasonography gives doctors precise images of the uterus and its surrounding structures, enabling them to evaluate the uterus's size, texture, and shape as well as identify anomalies such as masses or tumors. To identify diseases such as endometrial cancer, it can also measure the thickness of the endometrium.
Why Do Diagnostic Laboratories Enjoy a Significant Share of the Market?
“Availability of Qualified Medical Professionals and Technologically Advanced Equipment”
| Attribute | Diagnostic Laboratories |
|---|---|
| Segment Value (2024E) | US$ 1.33 Billion |
| Growth Rate (2024 to 2034) | 7.3% CAGR |
| Projected Value (2034F) | US$ 2.69 Billion |
Diagnostic laboratories are frequently outfitted with advanced technologies and specialized equipment needed for a variety of diagnostic tests, including those for uterine cancer. They act as centralized locations for the analysis of samples obtained from various healthcare settings (clinics, hospitals, etc.). Diagnostic laboratories have qualified medical personnel with specialized knowledge of accurately interpreting diagnostic tests, such as cytotechnologists, pathologists, and medical technologists. Rigorous quality standards are followed by accredited laboratories, guaranteeing accurate and consistent test results.
These labs provide a broad selection of diagnostic tests, such as molecular testing (genetic analysis, biomarker testing), histopathology (biopsies), cytology (Pap smears), and imaging (ultrasound, MRI). Uterine cancer and other conditions can be thoroughly evaluated thanks to this extensive test menu.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the uterine cancer diagnostic testing market are focusing on research initiatives are in vitro diagnostic tools tailored for gynecological cancers. These efforts aim to improve early detection and treatment monitoring using novel liquid biopsy techniques centered around gynecological fluids.
- Women's health start-up MiMARK Diagnostics raised US$ 4.53 million in November 2023 in its first seed funding round. As per the company, the money will be used to further their research in gynecological diagnostics, with a particular emphasis on the non-invasive biomarker detection method using gynecological fluids. In 2021, the company was granted US$ 1.61 million by EIT Health. With a focus on enhancing the diagnosis of endometrial cancer, MiMARK is creating in vitro diagnostic tools for the management of gynecological cancers. This method places gynecological fluid at the center of the next stage of gynecological liquid biopsy.
- The United States FDA approved Roche Holding AG's VENTANA MMR RxDx Panel endometrial cancer diagnostic kit in April 2022. This kit is intended to diagnose patients who are suitable for anti-PD1 immunotherapy, which involves JEMPERLI (dostarlimab-gxly) monotherapy. When used in conjunction with chemotherapy, this test can help clinicians diagnose patients and offer women with MMR-deficient endometrial cancer new options for treatment.
Fact.MR provides detailed information about the price points of key uterine cancer diagnostic testing providers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this updated market report.
Segmentation of Uterine Cancer Diagnostic Testing Market Research
-
By Cancer Type :
- Endometrial Carcinoma
- Uterine Sarcoma
-
By Diagnostic Test :
- Ultrasound Scanning
- Biopsy
- Blood Test
-
By End User :
- Hospitals
- Ambulatory Surgical Centers
- Cancer Research Centers
- Specialized Clinics
- Diagnostic Laboratories
- Others
-
By Region :
- North America
- Western Europe
- Eastern Europe
- East Asia
- Latin America
- South Asia & Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. Cancer Type 6.2. Diagnostic Test 6.3. End User 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Cancer Type 7.1. Endometrial Carcinoma 7.2. Uterine Sarcoma 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Diagnostic Test 8.1. Ultrasound Scanning 8.2. Biopsy 8.3. Blood Test 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User 9.1. Hospitals 9.2. Ambulatory Surgical Centers 9.3. Cancer Research Centers 9.4. Specialized Clinics 9.5. Diagnostic Laboratories 9.6. Others 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Eastern Europe 10.5. East Asia 10.6. South Asia & Pacific 10.7. Middle East & Africa 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Cancer Type, Diagnostic Test, End User, and Region for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Ariad Pharmaceuticals, Inc. 20.2. Abbott Laboratories 20.3. Becton, Dickinson & Co. 20.4. GlaxoSmithKline Plc 20.5. Merck & Co., Inc. 20.6. Novartis AG 20.7. Sanofi 20.8. Siemens Healthcare Inc. 20.9. Roche Ltd. 20.10. MiMARK Diagnostics 21. Assumptions and Acronyms Cancer Typed 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Diagnostic Test, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Diagnostic Test, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Diagnostic Test, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Diagnostic Test, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Diagnostic Test, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Diagnostic Test, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 28: Latin America Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 29: Latin America Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Diagnostic Test, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Diagnostic Test, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Diagnostic Test, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Western Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 41: Western Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 43: Western Europe Market Value (US$ Mn) Analysis, by Diagnostic Test, 2019 to 2023
Table 44: Western Europe Market Value (US$ Mn) Analysis, by Diagnostic Test, 2024 to 2034
Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Diagnostic Test, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Diagnostic Test, 2019 to 2023
Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Diagnostic Test, 2024 to 2034
Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Diagnostic Test, 2024 to 2034
Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: East Asia Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 65: East Asia Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 67: East Asia Market Value (US$ Mn) Analysis, by Diagnostic Test, 2019 to 2023
Table 68: East Asia Market Value (US$ Mn) Analysis, by Diagnostic Test, 2024 to 2034
Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Diagnostic Test, 2024 to 2034
Table 70: East Asia Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 71: East Asia Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Diagnostic Test, 2019 to 2023
Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Diagnostic Test, 2024 to 2034
Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Diagnostic Test, 2024 to 2034
Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 88: MEA Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 89: MEA Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 91: MEA Market Value (US$ Mn) Analysis, by Diagnostic Test, 2019 to 2023
Table 92: MEA Market Value (US$ Mn) Analysis, by Diagnostic Test, 2024 to 2034
Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Diagnostic Test, 2024 to 2034
Table 94: MEA Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 95: MEA Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Diagnostic Test, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Diagnostic Test, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Diagnostic Test, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by End User, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by End User, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 21: North America Market Share Analysis by Country, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Diagnostic Test, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Diagnostic Test, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Diagnostic Test, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 40: Latin America Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 41: Latin America Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 42: Latin America Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 43: Latin America Market Share and BPS Analysis by Diagnostic Test, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projections by Diagnostic Test, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Diagnostic Test, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 56: Western Europe Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 57: Western Europe Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 58: Western Europe Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 59: Western Europe Market Share and BPS Analysis by Diagnostic Test, 2024 & 2034
Figure 60: Western Europe Market Y-o-Y Growth Projections by Diagnostic Test, 2024 to 2034
Figure 61: Western Europe Market Attractiveness Analysis by Diagnostic Test, 2024 to 2034
Figure 62: Western Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: Eastern Europe Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 76: Eastern Europe Market Share and BPS Analysis by Diagnostic Test, 2024 & 2034
Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Diagnostic Test, 2024 to 2034
Figure 78: Eastern Europe Market Attractiveness Analysis by Diagnostic Test, 2024 to 2034
Figure 79: Eastern Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 80: Eastern Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 81: Eastern Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 89: East Asia Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 90: East Asia Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 91: East Asia Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 92: East Asia Market Share and BPS Analysis by Diagnostic Test, 2024 & 2034
Figure 93: East Asia Market Y-o-Y Growth Projections by Diagnostic Test, 2024 to 2034
Figure 94: East Asia Market Attractiveness Analysis by Diagnostic Test, 2024 to 2034
Figure 95: East Asia Market Share and BPS Analysis by End User, 2024 & 2034
Figure 96: East Asia Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 97: East Asia Market Attractiveness Analysis by End User, 2024 to 2034
Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 105: South Asia & Pacific Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 107: South Asia & Pacific Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 108: South Asia & Pacific Market Share and BPS Analysis by Diagnostic Test, 2024 & 2034
Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Diagnostic Test, 2024 to 2034
Figure 110: South Asia & Pacific Market Attractiveness Analysis by Diagnostic Test, 2024 to 2034
Figure 111: South Asia & Pacific Market Share and BPS Analysis by End User, 2024 & 2034
Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 113: South Asia & Pacific Market Attractiveness Analysis by End User, 2024 to 2034
Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 118: MEA Market Share Analysis by Country, 2024 & 2034
Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: MEA Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 122: MEA Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 123: MEA Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 124: MEA Market Share and BPS Analysis by Diagnostic Test, 2024 & 2034
Figure 125: MEA Market Y-o-Y Growth Projections by Diagnostic Test, 2024 to 2034
Figure 126: MEA Market Attractiveness Analysis by Diagnostic Test, 2024 to 2034
Figure 127: MEA Market Share and BPS Analysis by End User, 2024 & 2034
Figure 128: MEA Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 129: MEA Market Attractiveness Analysis by End User, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the uterine cancer diagnostic testing market in 2024?
The global uterine cancer diagnostic testing market is estimated at US$ 3.23 billion in 2024.
What are the sales projections for uterine cancer diagnostic testing over the decade?
The global market is forecasted to expand at 7.7% CAGR and reach US$ 6.76 billion by 2034.
Which country has a significant market for uterine cancer diagnostic testing?
The United States is estimated to at a market value of US$ 1.35 billion in 2024.
What is the market size of the uterine cancer diagnostic testing in Brazil?
The market in Brazil is forecasted to reach US$ 60.39 million in 2024.
How much share of the market do hospitals account for?
The hospital segment is expected to reach a market value of US$ 562.1 million in 2024.
What is the share of Chile in the Latin American market?
Chile accounts for 38.6% market share in Latin America in 2024.
Who are the leaders in the business of uterine cancer diagnostic testing?
Ariad Pharmaceuticals, Inc., Abbott Laboratories, Becton, Dickinson & Co. are some of the key players in this market.
Which tests are available for uterine cancer diagnostics?
Ultrasound scanning, biopsy, and blood tests are most widely performed for uterine cancer diagnostic testing.
Uterine Cancer Diagnostic Testing Market